Pharmacological Treatment of Heart Failure: Recent Advances.

IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Current Cardiology Reviews Pub Date : 2024-01-01 DOI:10.2174/011573403X270178231228061314

Jonathan C H Chan, Areeb Siddiqui

{"title":"Pharmacological Treatment of Heart Failure: Recent Advances.","authors":"Jonathan C H Chan, Areeb Siddiqui","doi":"10.2174/011573403X270178231228061314","DOIUrl":null,"url":null,"abstract":"Background: Heart failure is a clinical condition with high mortality and morbidity that occurs when the heart is unable to pump enough blood to meet the metabolic demands of the body. The pharmacological management of heart failure has been revolutionized over the past decade with novel treatments.Objective: The aim of the review is to highlight the recent pharmacological advances in the management of heart failure.Results: Sodium-glucose cotransporter-2 inhibitor (SGLT2i), iron carboxymaltose, finerenone, omecamtiv mecarbil, and vericiguat have been shown to reduce hospitalization for heart failure. However, only SGLT2i, vericiguat, and omecamtiv mecarbil have been shown to reduce cardiovascular death. Finerenone has been shown to reduce cardiovascular events and renal adverse outcomes in patients with diabetes and kidney disease. Currently, only SGLT2i has been studied in patients beyond the heart failure with reduced ejection fraction population.Conclusion: The current quadruple therapy in the treatment of heart failure has demonstrated a reduction in the hospitalization of patients and a decrease in mortality associated with the condition. Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"29-38"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011573403X270178231228061314","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Heart failure is a clinical condition with high mortality and morbidity that occurs when the heart is unable to pump enough blood to meet the metabolic demands of the body. The pharmacological management of heart failure has been revolutionized over the past decade with novel treatments.

Objective: The aim of the review is to highlight the recent pharmacological advances in the management of heart failure.

Results: Sodium-glucose cotransporter-2 inhibitor (SGLT2i), iron carboxymaltose, finerenone, omecamtiv mecarbil, and vericiguat have been shown to reduce hospitalization for heart failure. However, only SGLT2i, vericiguat, and omecamtiv mecarbil have been shown to reduce cardiovascular death. Finerenone has been shown to reduce cardiovascular events and renal adverse outcomes in patients with diabetes and kidney disease. Currently, only SGLT2i has been studied in patients beyond the heart failure with reduced ejection fraction population.

Conclusion: The current quadruple therapy in the treatment of heart failure has demonstrated a reduction in the hospitalization of patients and a decrease in mortality associated with the condition. Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

心力衰竭的药物治疗：最新进展。

背景：心力衰竭是一种死亡率和发病率都很高的临床病症，当心脏无法泵出足够的血液来满足机体的代谢需求时就会出现心力衰竭。过去十年间，心衰的药物治疗发生了革命性的变化，出现了新的治疗方法：综述旨在重点介绍心力衰竭药物治疗的最新进展：结果：钠-葡萄糖共转运体-2抑制剂（SGLT2i）、羧甲基铁、非诺酮、奥美卡米肼和维利奎特已被证明可减少心力衰竭的住院治疗。然而，只有 SGLT2i、vericiguat 和 omecamtiv mecarbil 能减少心血管死亡。菲尼酮已被证明可减少糖尿病和肾病患者的心血管事件和肾脏不良反应。目前，只有 SGLT2i 在心衰射血分数降低人群以外的患者中进行了研究：结论：目前治疗心力衰竭的四联疗法已证明可减少患者的住院时间，降低与心力衰竭相关的死亡率。个性化心衰治疗研究显示，部分心衰患者可从中获益。对新型疗法的进一步研究将有助于改善心衰患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Cardiology Reviews CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

3.70

自引率

10.50%

发文量

117

期刊介绍： Current Cardiology Reviews publishes frontier reviews of high quality on all the latest advances on the practical and clinical approach to the diagnosis and treatment of cardiovascular disease. All relevant areas are covered by the journal including arrhythmia, congestive heart failure, cardiomyopathy, congenital heart disease, drugs, methodology, pacing, and preventive cardiology. The journal is essential reading for all researchers and clinicians in cardiology.